New research from the University of Pittsburgh School of Medicine and La Jolla Institute for Immunology, published today in Nature Microbiology, reveals an opportunity for developing a therapy against cytomegalovirus (CMV), the leading infectious cause…
For patients with recessive dystrophic epidermolysis bullosa (RDEB), a one-time surgical application of prademagene zamikeracel, an autologous COL7A1 gene-modified cellular sheet that is sutured onto a large, chronic RDEB wound, improves wound healing …
Malaria is a life-threatening disease affecting people globally. It is spread by mosquitoes carrying Plasmodium parasites that infect and hide in red blood cells, making them difficult for the immune system to detect.
Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant laboratory experiments, scientists have uncovered how a pair of these lab-engineered molecules fight malaria.
Treating rare diseases can be complicated at the best of times, and it gets even more complicated when different patients with the same disease exhibit different symptoms. Now, researchers from Japan have reported a cellular signature that might explai…
The human body is naturally equipped with defenses to fight off viral infections. For a virus to successfully infect it, it must first overcome these defenses. To do so, viruses have evolved specialized tools—proteins known as “virulence factors”—that …
Diseases caused by human papillomavirus (HPV), such as cervical cancer, may have a new treatment option thanks to a technology developed by researchers at Imunotera Soluções Terapêuticas, a São Paulo startup incubated at Eretz.bio, the biotechnology st…
Primary sclerosing cholangitis, PSC in short, is a rare liver disease that destroys the bile ducts. It is a severe condition for which we currently have no effective treatments and often results in the patient requiring a liver transplant.
Scientists have discovered a unique class of small antibodies that are strongly protective against a wide range of SARS coronaviruses, including SARS-CoV-1 and numerous early and recent SARS-CoV-2 variants. The unique antibodies target an essential hig…
A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause immune-mediated tissue damage by targeting cells it has never infected.
